Summit Therapeutics Inc. (NASDAQ: SMMT) Stock Competitors & Peer Comparison
See SMMT's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for SMMT and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SMMT | $13.02 | -3.12% | 10.1B | -8.14 | -$1.60 | N/A |
| VRTX | $477.10 | -0.95% | 121.1B | 25.35 | $18.82 | N/A |
| REGN | $762.63 | +3.29% | 78.6B | 16.71 | $45.63 | +0.48% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $853.82 | -3.26% | 54.3B | 78.75 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $9.57 | -3.14% | 42.7B | -2.32 | -$4.15 | N/A |
| RVMD | $187.53 | -2.41% | 39.9B | -26.52 | -$7.07 | N/A |
| ONC | $316.01 | -1.88% | 33.8B | 70.70 | $4.47 | N/A |
| ALNY | $205.52 | -28.30% | 27.4B | 37.02 | $5.55 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
SMMT vs VRTX Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, VRTX has a market cap of 121.1B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while VRTX trades at $477.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas VRTX's P/E ratio is 25.35. In terms of profitability, SMMT's ROE is -2.04%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, SMMT is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
SMMT vs REGN Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, REGN has a market cap of 78.6B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while REGN trades at $762.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas REGN's P/E ratio is 16.71. In terms of profitability, SMMT's ROE is -2.04%, compared to REGN's ROE of +0.18%. Regarding short-term risk, SMMT is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
SMMT vs VRNA Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas VRNA's P/E ratio is -102.80. In terms of profitability, SMMT's ROE is -2.04%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, SMMT is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
SMMT vs ARGX Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, ARGX has a market cap of 54.3B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while ARGX trades at $853.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas ARGX's P/E ratio is 78.75. In terms of profitability, SMMT's ROE is -2.04%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, SMMT is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
SMMT vs SGEN Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas SGEN's P/E ratio is -57.19. In terms of profitability, SMMT's ROE is -2.04%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, SMMT is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check SGEN's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
SMMT vs RVMDW Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, RVMDW has a market cap of 42.7B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while RVMDW trades at $9.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas RVMDW's P/E ratio is -2.32. In terms of profitability, SMMT's ROE is -2.04%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, SMMT is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
SMMT vs RVMD Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, RVMD has a market cap of 39.9B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while RVMD trades at $187.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas RVMD's P/E ratio is -26.52. In terms of profitability, SMMT's ROE is -2.04%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, SMMT is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check RVMD's competition here
BeOne Medicines AG (NASDAQ: ONC)
SMMT vs ONC Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, ONC has a market cap of 33.8B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while ONC trades at $316.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas ONC's P/E ratio is 70.70. In terms of profitability, SMMT's ROE is -2.04%, compared to ONC's ROE of +0.12%. Regarding short-term risk, SMMT is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
SMMT vs ALNY Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, ALNY has a market cap of 27.4B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while ALNY trades at $205.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas ALNY's P/E ratio is 37.02. In terms of profitability, SMMT's ROE is -2.04%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, SMMT is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
SMMT vs ROIV Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, ROIV has a market cap of 24.5B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while ROIV trades at $33.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas ROIV's P/E ratio is -34.86. In terms of profitability, SMMT's ROE is -2.04%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, SMMT is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
SMMT vs INCY Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, INCY has a market cap of 24.2B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while INCY trades at $119.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas INCY's P/E ratio is 16.06. In terms of profitability, SMMT's ROE is -2.04%, compared to INCY's ROE of +0.30%. Regarding short-term risk, SMMT is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
SMMT vs BNTX Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while BNTX trades at $90.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas BNTX's P/E ratio is -19.61. In terms of profitability, SMMT's ROE is -2.04%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, SMMT is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
SMMT vs UTHR Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, UTHR has a market cap of 22B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while UTHR trades at $517.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas UTHR's P/E ratio is 19.10. In terms of profitability, SMMT's ROE is -2.04%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, SMMT is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check UTHR's competition here
Moderna, Inc. (NASDAQ: MRNA)
SMMT vs MRNA Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, MRNA has a market cap of 21.8B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while MRNA trades at $54.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas MRNA's P/E ratio is -6.73. In terms of profitability, SMMT's ROE is -2.04%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, SMMT is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check MRNA's competition here
Insmed Incorporated (NASDAQ: INSM)
SMMT vs INSM Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, INSM has a market cap of 21.4B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while INSM trades at $98.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas INSM's P/E ratio is -17.15. In terms of profitability, SMMT's ROE is -2.04%, compared to INSM's ROE of -1.30%. Regarding short-term risk, SMMT is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check INSM's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
SMMT vs BGNE Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas BGNE's P/E ratio is -22.55. In terms of profitability, SMMT's ROE is -2.04%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, SMMT is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
SMMT vs DNA-WT Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, SMMT's ROE is -2.04%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, SMMT is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check DNA-WT's competition here
Genmab A/S (NASDAQ: GMAB)
SMMT vs GMAB Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while GMAB trades at $28.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas GMAB's P/E ratio is 20.77. In terms of profitability, SMMT's ROE is -2.04%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, SMMT is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check GMAB's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
SMMT vs NBIX Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, NBIX has a market cap of 16.8B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while NBIX trades at $166.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas NBIX's P/E ratio is 24.10. In terms of profitability, SMMT's ROE is -2.04%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, SMMT is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
SMMT vs JAZZ Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, JAZZ has a market cap of 15.9B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while JAZZ trades at $252.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas JAZZ's P/E ratio is 19.66. In terms of profitability, SMMT's ROE is -2.04%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, SMMT is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
SMMT vs BBIO Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, BBIO has a market cap of 15.7B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while BBIO trades at $80.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas BBIO's P/E ratio is -21.41. In terms of profitability, SMMT's ROE is -2.04%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, SMMT is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
SMMT vs ASND Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, ASND has a market cap of 15.1B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while ASND trades at $243.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas ASND's P/E ratio is -100.79. In terms of profitability, SMMT's ROE is -2.04%, compared to ASND's ROE of -56.42%. Regarding short-term risk, SMMT is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
SMMT vs EXEL Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, EXEL has a market cap of 13.3B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while EXEL trades at $53.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas EXEL's P/E ratio is 15.88. In terms of profitability, SMMT's ROE is -2.04%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, SMMT is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check EXEL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
SMMT vs KRTX Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas KRTX's P/E ratio is -28.09. In terms of profitability, SMMT's ROE is -2.04%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, SMMT is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check KRTX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
SMMT vs ARWR Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, ARWR has a market cap of 11.9B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while ARWR trades at $84.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas ARWR's P/E ratio is -39.37. In terms of profitability, SMMT's ROE is -2.04%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, SMMT is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check ARWR's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
SMMT vs BMRN Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while BMRN trades at $60.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas BMRN's P/E ratio is 28.86. In terms of profitability, SMMT's ROE is -2.04%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, SMMT is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check BMRN's competition here
Bio-Techne Corporation (NASDAQ: TECH)
SMMT vs TECH Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while TECH trades at $72.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas TECH's P/E ratio is 37.16. In terms of profitability, SMMT's ROE is -2.04%, compared to TECH's ROE of +0.05%. Regarding short-term risk, SMMT is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
SMMT vs RNAM Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas RNAM's P/E ratio is -17.39. In terms of profitability, SMMT's ROE is -2.04%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, SMMT is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
SMMT vs AXSM Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, AXSM has a market cap of 11.2B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while AXSM trades at $217.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas AXSM's P/E ratio is -56.92. In terms of profitability, SMMT's ROE is -2.04%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, SMMT is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check AXSM's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
SMMT vs MDGL Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, MDGL has a market cap of 10.8B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while MDGL trades at $467.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas MDGL's P/E ratio is -36.51. In terms of profitability, SMMT's ROE is -2.04%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, SMMT is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check MDGL's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
SMMT vs KRYS Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, KRYS has a market cap of 10.1B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while KRYS trades at $341.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas KRYS's P/E ratio is 45.60. In terms of profitability, SMMT's ROE is -2.04%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, SMMT is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check KRYS's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
SMMT vs HALO Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, HALO has a market cap of 9.8B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while HALO trades at $82.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas HALO's P/E ratio is 17.87. In terms of profitability, SMMT's ROE is -2.04%, compared to HALO's ROE of +1.26%. Regarding short-term risk, SMMT is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check HALO's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
SMMT vs CYTK Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while CYTK trades at $77.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas CYTK's P/E ratio is -13.23. In terms of profitability, SMMT's ROE is -2.04%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, SMMT is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check CYTK's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
SMMT vs RXDX Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas RXDX's P/E ratio is -56.47. In terms of profitability, SMMT's ROE is -2.04%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, SMMT is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check RXDX's competition here
Abivax S.A. (NASDAQ: ABVX)
SMMT vs ABVX Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, ABVX has a market cap of 9.2B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while ABVX trades at $124.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas ABVX's P/E ratio is -65.48. In terms of profitability, SMMT's ROE is -2.04%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, SMMT is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check ABVX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
SMMT vs NUVL Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas NUVL's P/E ratio is -21.79. In terms of profitability, SMMT's ROE is -2.04%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, SMMT is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
SMMT vs CRNX Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, CRNX has a market cap of 8.8B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while CRNX trades at $83.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas CRNX's P/E ratio is -16.28. In terms of profitability, SMMT's ROE is -2.04%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, SMMT is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check CRNX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
SMMT vs PTGX Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, PTGX has a market cap of 8.8B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while PTGX trades at $136.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas PTGX's P/E ratio is -75.49. In terms of profitability, SMMT's ROE is -2.04%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, SMMT is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check PTGX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
SMMT vs IMGN Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas IMGN's P/E ratio is -111.55. In terms of profitability, SMMT's ROE is -2.04%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, SMMT is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check IMGN's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
SMMT vs IONS Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, IONS has a market cap of 8.6B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while IONS trades at $51.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas IONS's P/E ratio is -30.10. In terms of profitability, SMMT's ROE is -2.04%, compared to IONS's ROE of -1.11%. Regarding short-term risk, SMMT is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check IONS's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
SMMT vs PRAX Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, PRAX has a market cap of 8.6B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while PRAX trades at $307.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas PRAX's P/E ratio is -23.02. In terms of profitability, SMMT's ROE is -2.04%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, SMMT is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check PRAX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
SMMT vs SYRE Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, SYRE has a market cap of 8.5B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while SYRE trades at $98.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas SYRE's P/E ratio is -47.27. In terms of profitability, SMMT's ROE is -2.04%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, SMMT is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check SYRE's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
SMMT vs KYMR Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, KYMR has a market cap of 8.5B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while KYMR trades at $103.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas KYMR's P/E ratio is -29.29. In terms of profitability, SMMT's ROE is -2.04%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, SMMT is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check KYMR's competition here
Alkermes plc (NASDAQ: ALKS)
SMMT vs ALKS Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, ALKS has a market cap of 8.4B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while ALKS trades at $48.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas ALKS's P/E ratio is 52.66. In terms of profitability, SMMT's ROE is -2.04%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, SMMT is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check ALKS's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
SMMT vs BPMC Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas BPMC's P/E ratio is -51.58. In terms of profitability, SMMT's ROE is -2.04%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, SMMT is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
SMMT vs APGE Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while APGE trades at $134.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas APGE's P/E ratio is -30.97. In terms of profitability, SMMT's ROE is -2.04%, compared to APGE's ROE of -0.33%. Regarding short-term risk, SMMT is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check APGE's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
SMMT vs CERE Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas CERE's P/E ratio is -16.47. In terms of profitability, SMMT's ROE is -2.04%, compared to CERE's ROE of -0.72%. Regarding short-term risk, SMMT is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check CERE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
SMMT vs TGTX Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, TGTX has a market cap of 8B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while TGTX trades at $52.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas TGTX's P/E ratio is 17.88. In terms of profitability, SMMT's ROE is -2.04%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, SMMT is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check TGTX's competition here
Immunovant, Inc. (NASDAQ: IMVT)
SMMT vs IMVT Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, IMVT has a market cap of 7.9B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while IMVT trades at $38.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas IMVT's P/E ratio is -14.46. In terms of profitability, SMMT's ROE is -2.04%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, SMMT is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check IMVT's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
SMMT vs PCVX Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, PCVX has a market cap of 7.8B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while PCVX trades at $54.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas PCVX's P/E ratio is -7.86. In terms of profitability, SMMT's ROE is -2.04%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, SMMT is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check PCVX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
SMMT vs IBRX Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, IBRX has a market cap of 7.5B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while IBRX trades at $7.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas IBRX's P/E ratio is -8.44. In terms of profitability, SMMT's ROE is -2.04%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, SMMT is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check IBRX's competition here
Metsera, Inc. (NASDAQ: MTSR)
SMMT vs MTSR Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas MTSR's P/E ratio is -23.58. In terms of profitability, SMMT's ROE is -2.04%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, SMMT is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check MTSR's competition here
Merus N.V. (NASDAQ: MRUS)
SMMT vs MRUS Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas MRUS's P/E ratio is -17.05. In terms of profitability, SMMT's ROE is -2.04%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, SMMT is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check MRUS's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
SMMT vs RYTM Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, RYTM has a market cap of 6.8B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while RYTM trades at $99.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas RYTM's P/E ratio is -31.71. In terms of profitability, SMMT's ROE is -2.04%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, SMMT is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check RYTM's competition here
Arcellx, Inc. (NASDAQ: ACLX)
SMMT vs ACLX Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas ACLX's P/E ratio is -28.27. In terms of profitability, SMMT's ROE is -2.04%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, SMMT is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check ACLX's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
SMMT vs COGT Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, COGT has a market cap of 6.7B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while COGT trades at $38.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas COGT's P/E ratio is -18.45. In terms of profitability, SMMT's ROE is -2.04%, compared to COGT's ROE of -0.83%. Regarding short-term risk, SMMT is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check COGT's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
SMMT vs RETA Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas RETA's P/E ratio is -66.29. In terms of profitability, SMMT's ROE is -2.04%, compared to RETA's ROE of +0.47%. Regarding short-term risk, SMMT is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check RETA's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
SMMT vs MIRM Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, MIRM has a market cap of 6.5B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while MIRM trades at $105.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas MIRM's P/E ratio is -7.78. In terms of profitability, SMMT's ROE is -2.04%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, SMMT is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check MIRM's competition here
Belite Bio, Inc (NASDAQ: BLTE)
SMMT vs BLTE Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while BLTE trades at $158.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas BLTE's P/E ratio is -84.82. In terms of profitability, SMMT's ROE is -2.04%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, SMMT is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check BLTE's competition here
Erasca, Inc. (NASDAQ: ERAS)
SMMT vs ERAS Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, ERAS has a market cap of 6.3B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while ERAS trades at $18.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas ERAS's P/E ratio is -19.51. In terms of profitability, SMMT's ROE is -2.04%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, SMMT is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check ERAS's competition here
CG Oncology Inc. (NASDAQ: CGON)
SMMT vs CGON Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while CGON trades at $71.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas CGON's P/E ratio is -30.55. In terms of profitability, SMMT's ROE is -2.04%, compared to CGON's ROE of -0.23%. Regarding short-term risk, SMMT is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check CGON's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
SMMT vs CNTA Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas CNTA's P/E ratio is -22.63. In terms of profitability, SMMT's ROE is -2.04%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, SMMT is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check CNTA's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
SMMT vs XENE Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, XENE has a market cap of 6.1B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while XENE trades at $62.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas XENE's P/E ratio is -13.33. In terms of profitability, SMMT's ROE is -2.04%, compared to XENE's ROE of -0.49%. Regarding short-term risk, SMMT is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check XENE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
SMMT vs LGND Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while LGND trades at $287.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas LGND's P/E ratio is 34.48. In terms of profitability, SMMT's ROE is -2.04%, compared to LGND's ROE of +0.16%. Regarding short-term risk, SMMT is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check LGND's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
SMMT vs SRRK Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while SRRK trades at $47.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas SRRK's P/E ratio is -13.17. In terms of profitability, SMMT's ROE is -2.04%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, SMMT is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check SRRK's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
SMMT vs PTCT Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, PTCT has a market cap of 5.6B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while PTCT trades at $68.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas PTCT's P/E ratio is -29.19. In terms of profitability, SMMT's ROE is -2.04%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, SMMT is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check PTCT's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
SMMT vs CDTX Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas CDTX's P/E ratio is -19.77. In terms of profitability, SMMT's ROE is -2.04%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, SMMT is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
SMMT vs ABCM Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, SMMT's ROE is -2.04%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, SMMT is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
SMMT vs ISEE Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas ISEE's P/E ratio is -22.44. In terms of profitability, SMMT's ROE is -2.04%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, SMMT is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
SMMT vs APLS Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas APLS's P/E ratio is 38.35. In terms of profitability, SMMT's ROE is -2.04%, compared to APLS's ROE of +0.40%. Regarding short-term risk, SMMT is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check APLS's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
SMMT vs TVTX Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, TVTX has a market cap of 5.2B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while TVTX trades at $55.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas TVTX's P/E ratio is -254.05. In terms of profitability, SMMT's ROE is -2.04%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, SMMT is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check TVTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
SMMT vs TERN Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas TERN's P/E ratio is -51.41. In terms of profitability, SMMT's ROE is -2.04%, compared to TERN's ROE of -0.20%. Regarding short-term risk, SMMT is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check TERN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
SMMT vs DFTX Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while DFTX trades at $43.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas DFTX's P/E ratio is N/A. In terms of profitability, SMMT's ROE is -2.04%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, SMMT is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check DFTX's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
SMMT vs DYN Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, DYN has a market cap of 4.6B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while DYN trades at $25.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas DYN's P/E ratio is -7.82. In terms of profitability, SMMT's ROE is -2.04%, compared to DYN's ROE of -0.64%. Regarding short-term risk, SMMT is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check DYN's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
SMMT vs CRSP Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while CRSP trades at $47.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas CRSP's P/E ratio is -9.39. In terms of profitability, SMMT's ROE is -2.04%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, SMMT is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check CRSP's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
SMMT vs FOLD Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas FOLD's P/E ratio is -161.00. In terms of profitability, SMMT's ROE is -2.04%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, SMMT is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
SMMT vs AKRO Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas AKRO's P/E ratio is -14.57. In terms of profitability, SMMT's ROE is -2.04%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, SMMT is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check AKRO's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
SMMT vs DNTH Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, DNTH has a market cap of 4.5B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while DNTH trades at $106.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas DNTH's P/E ratio is -25.89. In terms of profitability, SMMT's ROE is -2.04%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, SMMT is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check DNTH's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
SMMT vs ALPN Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas ALPN's P/E ratio is -101.52. In terms of profitability, SMMT's ROE is -2.04%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, SMMT is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check ALPN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
SMMT vs ACAD Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, ACAD has a market cap of 4.4B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while ACAD trades at $25.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas ACAD's P/E ratio is 12.68. In terms of profitability, SMMT's ROE is -2.04%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, SMMT is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check ACAD's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
SMMT vs CAI Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while CAI trades at $15.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas CAI's P/E ratio is -86.19. In terms of profitability, SMMT's ROE is -2.04%, compared to CAI's ROE of +0.06%. Regarding short-term risk, SMMT is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check CAI's competition here
Veradermics, Incorporated (NYSE: MANE)
SMMT vs MANE Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, MANE has a market cap of 4.4B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while MANE trades at $105.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas MANE's P/E ratio is -33.36. In terms of profitability, SMMT's ROE is -2.04%, compared to MANE's ROE of -0.84%. Regarding short-term risk, SMMT is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check MANE's competition here
Opthea Limited (NASDAQ: OPT)
SMMT vs OPT Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas OPT's P/E ratio is -1.52. In terms of profitability, SMMT's ROE is -2.04%, compared to OPT's ROE of +1.18%. Regarding short-term risk, SMMT is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
SMMT vs PRTC Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas PRTC's P/E ratio is -3.78. In terms of profitability, SMMT's ROE is -2.04%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, SMMT is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check PRTC's competition here
Celcuity Inc. (NASDAQ: CELC)
SMMT vs CELC Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, CELC has a market cap of 4.2B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while CELC trades at $86.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas CELC's P/E ratio is -22.15. In terms of profitability, SMMT's ROE is -2.04%, compared to CELC's ROE of -2.45%. Regarding short-term risk, SMMT is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check CELC's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
SMMT vs EWTX Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, EWTX has a market cap of 4.1B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while EWTX trades at $38.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas EWTX's P/E ratio is -23.15. In terms of profitability, SMMT's ROE is -2.04%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, SMMT is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check EWTX's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
SMMT vs MRTX Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas MRTX's P/E ratio is -4.82. In terms of profitability, SMMT's ROE is -2.04%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, SMMT is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check MRTX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
SMMT vs ELVN Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, ELVN has a market cap of 3.9B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while ELVN trades at $54.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas ELVN's P/E ratio is -32.82. In terms of profitability, SMMT's ROE is -2.04%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, SMMT is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check ELVN's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
SMMT vs CPRX Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas CPRX's P/E ratio is 12.30. In terms of profitability, SMMT's ROE is -2.04%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, SMMT is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check CPRX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
SMMT vs RYZB Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas RYZB's P/E ratio is -57.86. In terms of profitability, SMMT's ROE is -2.04%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, SMMT is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
SMMT vs CBAY Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas CBAY's P/E ratio is -32.81. In terms of profitability, SMMT's ROE is -2.04%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, SMMT is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check CBAY's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
SMMT vs VKTX Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while VKTX trades at $31.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas VKTX's P/E ratio is -7.67. In terms of profitability, SMMT's ROE is -2.04%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, SMMT is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check VKTX's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
SMMT vs DNLI Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while DNLI trades at $23.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas DNLI's P/E ratio is -7.99. In terms of profitability, SMMT's ROE is -2.04%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, SMMT is less volatile compared to DNLI. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check DNLI's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
SMMT vs ORKA Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, ORKA has a market cap of 3.6B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while ORKA trades at $96.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas ORKA's P/E ratio is -49.75. In terms of profitability, SMMT's ROE is -2.04%, compared to ORKA's ROE of -0.26%. Regarding short-term risk, SMMT is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check ORKA's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
SMMT vs ADPT Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while ADPT trades at $22.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas ADPT's P/E ratio is -41.80. In terms of profitability, SMMT's ROE is -2.04%, compared to ADPT's ROE of -0.31%. Regarding short-term risk, SMMT is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check ADPT's competition here
Alumis Inc. (NASDAQ: ALMS)
SMMT vs ALMS Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, ALMS has a market cap of 3.6B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while ALMS trades at $28.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas ALMS's P/E ratio is -7.39. In terms of profitability, SMMT's ROE is -2.04%, compared to ALMS's ROE of -0.55%. Regarding short-term risk, SMMT is less volatile compared to ALMS. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check ALMS's competition here
Arcus Biosciences, Inc. (NYSE: RCUS)
SMMT vs RCUS Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, RCUS has a market cap of 3.5B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while RCUS trades at $28.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas RCUS's P/E ratio is -8.66. In terms of profitability, SMMT's ROE is -2.04%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, SMMT is more volatile compared to RCUS. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check RCUS's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
SMMT vs SWTX Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas SWTX's P/E ratio is -13.78. In terms of profitability, SMMT's ROE is -2.04%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, SMMT is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for SMMT.Check SWTX's competition here
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT)
SMMT vs ARQT Comparison August 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMMT stands at 10.1B. In comparison, ARQT has a market cap of 3.5B. Regarding current trading prices, SMMT is priced at $13.02 on the NASDAQ, while ARQT trades at $26.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMMT currently has a P/E ratio of -8.14, whereas ARQT's P/E ratio is -933.00. In terms of profitability, SMMT's ROE is -2.04%, compared to ARQT's ROE of -0.01%. Regarding short-term risk, SMMT is less volatile compared to ARQT. This indicates lower risk in terms of short-term price fluctuations for SMMT.Check ARQT's competition here